SymBiosis is a venture capital firm primarily focused on advancing biotherapeutics innovations. They invest across disease areas, financing stages, and geographies, with a particular emphasis on private companies that have programs in, or are about to enter, human trials.
100% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $80.8M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 R1 Therapeutics | Series A | $77.5M | Mar 2026 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
| Evommune, Inc. | Series B | $50M | Apr 2023 |
Top Co-Investors
Pivotal bioVenture Partners2 shared
EQT Life Sciences2 shared
Andera Partners2 shared
Amplitude Ventures2 shared
RA Capital Management1 shared
Sectoral Asset Management1 shared
B Capital1 shared
Marshall Wace1 shared
Avego BioScience Capital1 shared
Longwood Fund1 shared
RTW Investments1 shared
Beiersdorf1 shared
Arix Bioscience1 shared
Abingworth1 shared
DaVita Venture Group1 shared
F-Prime Capital1 shared
Last updated: 16 April 2026